The study of Prostate Cancer Incidence over a Period of 5 years (2014-2020) in Saveh city

Document Type : Original article

Authors

1 department of anatomy, Saveh university of medical sciences, Saveh, Iran

2 Assistant Professor, Department of Nursing, Saveh University of Medical Sciences, Saveh, Iran

3 Assistant Professor, Department of Physiology, Saveh University of Medical Sciences, Saveh, Iran

4 Assistant Professor, Department of Anatomy, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective: Prostate cancer is one of the leading causes of death in men, so that this cancer is the most common and the second leading cause of death in men. Therefore, in this study, the epidemiological study of prostate cancer in a period of 5 years from 1393 to 1397 in Saveh has been done.

Materials and Methods: This is a descriptive cross-sectional study using the re-analysis of the data of the annual report of cases registered in the Cancer Registration Center during the years 93 to 97 (because the information after 97 is still fully collected and Not registered) has been done in Saveh city. The study was performed based on the total number of cases, age of onset of the disease and data used in the cancer registry program during this period

Results: The results of this study showed that the number of registered cases of total cancers is also increasing and with age the number of registered cases of prostate cancer increased significantly and the highest number of people with this disease are people older than 80 years old.

Conclusion: Prostate cancer is a disease that is more common in older men and its incidence is increasing in Saveh. Due to the aging population and lifestyle changes, proper planning for accurate and timely examinations for early diagnosis and treatment of this cancer seems necessary.

Keywords

References

1. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. European urology. 2020;77(4):508-47 .
2. Giona S. The Epidemiology of Prostate Cancer. Exon Publications. 2021:1-15.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
4. Askari F, Parizi M, Rashidkhani B. Dietary patterns and prostate cancer: a case-control study. Iranian Journal of Nutrition Sciences & Food Technology. 2013;8(3):17-25 .
5. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11(5):1388-413.
6. Crawford ED. Epidemiology of prostate cancer .Urology. 2003;62(6):3-12 .
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians.2010;60(5):277-300 .
8. Grosclaude P, Belot A, Remontet L, Leone N, Bossard N, Velten M. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Progres en Urologie: Journal de L'association Francaise D'urologie et de la Societe Francaise D'urologie. 2015;25(9):536-42.
9. Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Current oncology reports. 2021;23(2):1-10 .
 10. Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate cancer and prostatic diseases. 2021;24(3):623-37 .
11. Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019;10(2):63.
12. Merriel SW, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of
prostate cancer in symptomatic patients. BMC medicine. 2022;20(1):1-11 .
13. Abbasi M, Basiri S. Prostate Cancer: A Case Report. Journal of Research in Urology. 2017;2(1):29-32 .
14. Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nature Reviews Urology. 2019;16(5):302-17 .
15. Farahmand M, Khademolhosseini F, Mehrabani D. Trend of prostate cancer in Fars Province, Southern Iran, 2001-2007. Journal of research in medical sciences: the official journal of IsfahanUniversity of Medical Sciences. 2010;15(5):295 .
16. Zorlu F, Divrik RT, Eser S, Yorukoglu K. Prostate cancer incidence in Turkey: an epidemiologicalstudy. 2014 .
17. Hosseini M, SeyedAlinaghi SA, Mahmoudi M, McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta medica Iranica. 2010:61-6 .
18.Chinegwundoh FI. The relationship between Black men with prostate cancer and their health-care providers. Nature Reviews Urology. 2021;18(12): 701-2 .
19.Sivoňová MK, Kaplán P, Tatarková Z, Lichardusová L, Dušenka R, Jurečeková J. Androgen receptor and soy isoflavones in prostate cancer. Molecular and clinical oncology. 2019;10(2):191-204 .
20. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. European urology. 2020;77(1):38-52 .
21. Rafimanesh H, Ghoncheh M, Salehinia H, Mohammadian Hafashjani A. Epidemiology of prostate cancer and its incidence trends in Iran. Journal of Sabzevar University of Medical Sciences. 2016;23(2):320-7 
Navid No
Volume 25, Issue 83
December 2022
Pages 58-67

Files

Share

How to cite

Statistics